GlassScriptPhysician profile
Youssef Makki
NPI 1447825989
$5,335.57
in general payments reported to CMS, 2019-2025
21 companies · $1,920 in 2025
The $1,920 reported for 2025 was more than what 92% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $222 · 2022: $713 · 2023: $1,027 · 2024: $1,453 · 2025: $1,920.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,383 · Education: $17.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,383.04 |
| Education | $17.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $978.08 | 2021-2025 | Caplyta |
| Alkermes, INC. | $799.09 | 2022-2025 | Aristada, Lybalvi |
| Abbvie INC. | $753.52 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $728.48 | 2021-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Lundbeck LLC | $628.60 | 2022-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $451.19 | 2021-2025 | Ingrezza |
| Supernus Pharmaceuticals, INC. | $129.97 | 2022-2025 | Qelbree, Qelbree |
| Axsome Therapeutics, INC. | $120.18 | 2023-2025 | Auvelity |
| Corium, LLC | $109.31 | 2022-2024 | Azstarys |
| Orexo US, INC. | $107.22 | 2022-2025 | Zubsolv |
| Vanda Pharmaceuticals INC. | $96.08 | 2025 | Fanapt |
| Janssen Pharmaceuticals, INC | $88.88 | 2022-2025 | Invega Sustenna, Spravato |
| Teva Pharmaceuticals USA, INC. | $79.92 | 2023-2025 | Austedo Xr, Uzedy |
| Tris Pharma INC | $71.25 | 2023-2025 | Dyanavel Xr |
| Ironshore Pharmaceuticals INC. | $49.33 | 2023-2024 | Jornay Pm |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sage Therapeutics, LLC | $43.26 | 2025 | Zurzuvae |
| Collegium Pharmaceutical, INC. | $24.90 | 2025 | Jornay Pm |
| Takeda Pharmaceuticals U.S.A., INC. | $24.85 | 2024 | Trintellix |
| Noven Therapeutics, LLC | $18.41 | 2025 | Xelstrym |
| Merck Sharp & Dohme LLC | $17.19 | 2023 | Belsomra |
| Luye Pharma (USA) LTD. | $15.86 | 2025 | Erzofri Extended-Release |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Youssef Makki listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.